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Abstract 
We examined the importance of molecular weight on the absorption from the liver 
surface in rats using fluorescein isothiocyanate-dextrans (FDs) with molecular weights 
of 4,400 (FD-4), 9,300 (FD-10), 40,500 (FD-40) or 69,000 (FD-70).   After 
application of FDs (5 mg) to the rat liver surface employing a cylindrical glass cell (i.d. 
9 mm), each FD appeared gradually in the plasma, and the in vivo behavior was 
explained by two-compartment model with first-order absorption.   The absorption 
ratios of FDs from the rat liver surface at 6 h, calculated from the amount recovered 
from the glass cell, decreased with an increase in the molecular weight (44.5 % for 
FD-4, 29.3 % for FD-10, 5.1 % for FD-40 and 2.2 % for FD-70).   A linear 
relationship was observed between the absorption rate constant and the reciprocal value 
with square root of molecular weight of the model compounds.   The limit of 
absorption from the rat liver surface was extrapolated to be at a molecular weight of 
70,000.   Furthermore, absorbed FDs were accumulated in the liver, as high liver / 
plasma concentration ratio as compared with that of i.v. administration. 
We clarified the molecular weight dependence of drug absorption from the liver 
surface in rats.   Moreover, the liver surface application appeared to be a promising 
route with enhancing the efficacy of drug targeting to the liver. 
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Previously (Nishida et al., 1994), we reported the possibility of the drug absorption 
from the liver surface in rats, by using organic anions as model drugs, aiming to develop 
a new administration route for improving the treatment of liver disease.   Furthermore, 
we examined the effect of protein binding on the drug absorption from the liver surface, 
and demonstrated that protein binding tended to suppress the absorption of model drugs 
and that its inhibitory effect was closely correlated with the tightness of their binding to 
bovine serum albumin (Nishida et al., 1995b). 
Since molecular weight seemed to play an important role in drug absorption from 
the liver surface membrane, the absorption mechanism of macromolecules itself needs 
to be carefully examined for clinical application of macromolecules such as biologically 
active peptides.   There are some reports concerning the molecular weight dependence 
of peritoneal transport (Flessner et al., 1985a; Leypoldt et al., 1987a; Nagy et al., 1989; 
Seymour et al., 1987; Yamaoka et al., 1995b) and the accumulation of macromolecules 
in several organs after intraperitoneal administration (Flessner et al., 1992; Seymour et 
al., 1991).   However, the absorption characteristics of macromolecules across the 
surface membrane of a particular organ involving the liver is still unknown. 
In the present study, we selected four types of fluorescein isothiocyanate-dextran 
with various molecular weights as model macromolecules and studied their in vivo 
pharmacokinetics after application to the rat liver surface.   Dextrans are glucose 
polymers which are available in different molecular weights, and have been suggested 
to be possible macromolecular carriers for delivery of drugs (Larsen, 1989; Sezaki et al., 
1989).   Additionally, dextrans are fairly resistant to metabolic degradation and their 
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in vivo fate has been characterized fully in rats (Mehvar & Shepard, 1992; Mehvar et al., 
1994; Nishida et al., 1991). 
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MATERIALS AND METHODS 
 
Chemicals 
Fluorescein isothiocyanate-dextrans (FDs) with average molecular weights of 4,400 
(FD-4), 9,300 (FD-10), 40,500 (FD-40) or 69,000 (FD-70), and bovine serum albumin 
(BSA; fraction V) were obtained from Sigma Chemical Co. (St. Louis, U.S.A.).   
Evan’s blue (EB) was purchased from Nacalai Tesque, Inc. (Kyoto, Japan).   All other 
chemicals were reagent grade products. 
 
In vivo experiment 
All animal procedures in the present study conformed to the Guidelines for Animal 
Experimentation in Nagasaki University. 
Male Wistar rats (230 - 250 g) were anesthetized with sodium pentobarbital (50 
mg/kg, i.p.) and the left femoral artery was cannulated with a polyethylene tube (i.d. 0.5 
mm, o.d. 0.8 mm; Dural Plastics, Dural, Australia).   After the middle abdomen was 
cut open about 3 cm, the common bile duct was cannulated with a polyethylene tube (i.d. 
0.28 mm, o.d. 0.61 mm; Becton Dickinson & Co., Parsippany, U.S.A.).   The body 
temperature of the rats was kept at 37°C with a heat lamp during the experiment.   The 
test solution of FDs was prepared in an isotonic phosphate buffer (pH 7.4) to yield a 
concentration of 5 mg/0.1 ml, and administered as follows. 
I.v. administration: The test solution (50 mg/ml X 0.1 ml) was injected into the 
jugular vein in rats. 
Application to the liver surface: A cylindrical glass cell (i.d. 9 mm, effective area 
0.64 cm2) was attached to the rat liver surface at the area of the left lobe with Aron 
Alpha (Sankyo Co. Ltd, Tokyo, Japan), and the test solution (50 mg/ml X 0.1 ml) was 
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added to the glass cell directly.   In other experiments, EB (2 mg/ml) - BSA (5 % 
W/V) solution was applied to the rat liver surface.   The top of the glass cell was 
sealed with a piece of aluminum foil to prevent the evaporation of the applied solution. 
The blood samples were collected at selected times from the heparinized cannula 
inserted into the femoral artery over a 3- or 6-h period, and were centrifuged at 15,000 
rpm for 5 min.   The bile samples were collected at appropriate time intervals.   At 3 
or 6 h after the dosing, the urine remaining in the bladder was collected directly with a 
syringe, followed by excision of the liver.   For application to the liver surface, the 
solution remaining in the glass cell at 6 h after dosing was withdrawn by more than five 
washings with saline before the liver was excised.   Also, the time course studies on 




The concentrations of FDs as fluorescence in the plasma, bile, urine and solution 
remaining in the glass cell were measured by a spectrophotofluorometer at excitation 
and emission wavelengths of 489 and 515 nm, respectively.   The FDs concentration 
in the liver was determined as follows.   The excised liver was homogenized in an 
equal volume of its weight of distilled water.   After 10 ml of acetone was added to 5 
ml of the liver homogenate, the mixture was shaken for 15 min, followed by 
centrifugation for 15 min at 3,000 rpm.   The FDs concentration as fluorescence in the 
resulting supernatant was determined in the same manner as described above. 
The concentration of EB (EB-BSA) was determined spectrophotometrically at 
615 nm after dilution with an isotonic phosphate buffer (pH 7.4). 
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Compartment model analysis 
First, the plasma concentration (Cp) profile of FDs after i.v. administration was fitted to 
the biexponential equation described as follows, by the nonlinear least-squares method 





















α β21 21  (1) 
Hybrid parameters α and β are defined as α + β = K12 + K21 + Kel and α · β = K21 · Kel.   
Vc is the volume of the central compartment.   Kel is the first-order elimination rate 
constant from the central compartment.   K12 and K21 are the first-order transfer rate 
constants between the central and peripheral compartment.   The total body clearance 
(CLtotal) and area under the plasma concentration profile (AUCp) was obtained by Kel · 
Vc and Dose/CLtotal, respectively. 
Next, in the same way, the plasma concentration profile of FDs after application 
to the rat liver surface was fitted in a two-compartment model incorporating first-order 
absorption, by the nonlinear least-squares method (Yamaoka et al., 1981).   In this 




















































Ka is the first-order absorption rate constant for absorption into the blood stream from 
the rat liver surface.   F is the availability of FDs after application to the rat liver 
surface.   In the case of curve-fitting of plasma concentration profile of FDs after 
application to the rat liver surface, the pharmacokinetic parameters (α, β, K21, Vc) 
obtained from the plasma concentration profile after i.v. administration were substituted 
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In vivo elimination of FDs after i.v. administration 
First, the plasma concentrations of FDs with different average molecular weights were 
determined for 3 h after i.v. administration to rats at a dose of 5 mg, and were illustrated 
in Figure 1.   All FDs showed biphasic elimination from the plasma, as shown in 
Figure 1.   Table 1 summarizes the pharmacokinetic parameters for FDs calculated on 
the basis of the two-compartment model.   FD-4 and FD-10 showed a large clearance 
from the plasma, while FD-40 and FD-70 had a small total body clearance.   Thus, a 
marked difference was observed in systemic clearance between FD-10 and FD-40.   
This phenomenon was well consistent with the previous finding that dextrans with low 
molecular weight were cleared from the body by tubular filtration, while the vascular 
permeability at the glomeruli was negligible at a molecular weight of 30,000, owing to 
restriction by pore size of vascular beds in the kidney (Brenner et al., 1978; Leypoldt et 
al., 1987b). 
 
Plasma concentration profiles of FDs after application to the rat liver surface 
Figure 2 illustrates the plasma concentration profiles of FDs with different molecular 
weights after application to the rat liver surface at a dose of 5 mg.   All FDs were 
absorbed from the liver surface, followed by progressive appearance into the plasma.   
For FD-40 and FD-70, the plasma levels either plateaued or continued to rise until 6 h 
after dosing.   Also, the appearance of FDs in the plasma was delayed with an increase 
in the molecular weight of FDs, suggesting that the absorption rate of FDs with high 
molecular weight is low. 
Recovery of FDs in the glass cell, bile, urine and liver 
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Table 2 shows the recovery in 6 h of FDs with different molecular weights in the glass 
cell, bile, urine and liver after application to the rat liver surface at a dose of 5 mg, 
along with that in 3 h after i.v. administration for comparison.   The absorption ratios 
of FDs from the rat liver surface at 6 h were calculated from the amount recovered from 
the glass cell, as 44.5 % for FD-4, 29.3 % for FD-10, 5.1 % for FD-40 and 2.2 % for 
FD-70.   An increase in the molecular weight of FDs resulted in the decrease of 
absorption rate from the rat liver surface. 
We added the data of BSA labeled with EB (EB-BSA) after application to the rat 
liver surface.   The absorption ratio of EB-BSA in 6 h was calculated to be 3.6 ± 0.8 % 
of dose (mean ± S.E., N=5) from the amount recovered from the glass cell. 
Similar to i.v. administration, each FD was excreted mainly into the urine in 
proportion to the absorbed amount after application to the rat liver surface, while the 
biliary recovery was less than 1 % of the dose.   A considerable amount of FDs was 
found in the liver at 6 h after application to the rat liver surface (Table 2).   The 
recovery of FDs in the liver was slightly larger than that after i.v. administration (3 h 
after dosing), although FDs applied to the rat liver surface were not absorbed 
completely.   Also, the liver / plasma concentration ratio of FDs at 6 h after 
application to the rat liver surface was high (9.3 for FD-4, 11.5 for FD-10, 3.8 for 
FD-40 and 3.0 for FD-70), as compared with that of i.v. administration at 3 h (2.9 for 
FD-4, 5.6 for FD-10, 0.3 for FD-40 and 0.03 for FD-70). 
 
Distribution of FD-4 and FD-10 in the glass cell, plasma, bile and urine after 
application to the rat liver surface 
To assess the absorption characteristics from the rat liver surface membrane, we studied 
the distribution pattern of FDs after application to the rat liver surface.   We selected 
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FD-4 and FD-10 as a model, because their absorbability was relatively good (Table 2). 
Figure 3 shows the time courses of distribution of FD-4 and FD-10 in the glass 
cell, plasma, bile and urine after application to the rat liver surface at a dose of 5 mg.   
The amount of FD-4 and FD-10 remaining in the plasma determined as Cp X Vplasma was 
small (< 1 % of dose), where Vplasma (plasma volume in rat) was estimated from reported 
values (45 ml/kg) by Bischoff et al. (1971).   The amount of FD-4 and FD-10 
remaining in the glass cell declined at different rates, as shown in Figures 3A and 3B.   
A cumulative amount of FD-4 and FD-10 excreted into the urine increased with time, 
with the decrease in the amount of FD-4 and FD-10 in the glass cell 
A semi-log plot of time course of the amount of FD-4 and FD-10 remaining in the 
glass cell gave a straight line (correlation coefficient: 0.99 for FD-4 and 0.95 for FD-10), 
as shown in Figure 4.   This suggests that the absorption of FDs from the rat liver 
surface proceeds via first-order kinetics, similar to the case of small molecule phenol 
red (Nishida et al., 1995a).   The first-order absorption rate constant Ka for FD-4 and 
FD-10 was calculated to be 157.2 X 10-5 and 92.4 X 10-5 min-1, respectively (Table 3). 
 
Compartment model analysis of plasma concentration profile after application to 
the rat liver surface 
We constructed the two-compartment model with first-order absorption based on the 
biexponential elimination after i.v. administration, to explain the in vivo behavior of 
FDs after application to the rat liver surface.   Ka values of FDs were estimated by the 
elimination profile from the glass cell (Figure 4) or curve-fitting of plasma 
concentration profile according to Eq. (2), and are summarized in Table 3.   On the 
other hand, F values of FDs were also obtained by curve-fitting of plasma concentration 
profile, and calculated to be approximately 100 % for every FD.   In the case of FD-40 
12 
and FD-70, the Ka value through the elimination profile from the glass cell was 
estimated by using the absorption ratio at 6 h after dosing, because we could not obtain 
a correct first-order elimination pattern owing to their low absorption rate. 
To clarify the validity of the pharmacokinetic model, we performed the simulation 
of plasma concentration according to Eq. (2) by use of the parameters given in Table 3, 
and compared it with the experimentally observed data (Figure 2).   Each symbol is 
the experimental value, and the solid and broken lines show the simulation curves 
reconstructed employing the estimated Ka and F values obtained through the elimination 
profile or curve-fitting (Table 3), respectively.   In the case of simulation employing 
the parameters through the elimination profile, the simulation curves was reconstructed 
by assuming that F is 100 %.   In general, good agreement was observed between the 
simulation curves and experimentally observed values of FDs in both methods as shown 
in Figure 2, suggesting the validity of this pharmacokinetic model.   As listed in Table 
3, Ka values of FDs calculated by the curve-fitting correlated closely with those 
calculated by the elimination profile, supporting the present fitting procedure. 
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DISCUSSION 
We examined the absorbability of macromolecules from the liver surface and its 
dependence of molecular weight, and demonstrated clearly that FDs with different 
molecular weights as model macromolecules were absorbed from the liver surface at 
different rates and that the absorption rate obeyed the first-order kinetics.   Also, we 
indicated that the in vivo behavior of FDs after application to the rat liver surface was 
well described by a two-compartment model with first-order absorption.   The 
calculated Ka for FDs decreased with the increase in the molecular weight (Table 3), 
suggesting that the drug absorption from the liver surface was affected greatly by the 
molecular weight.   When considering the clinical application of macromolecular drug, 
it is important to examine the molecular weight dependence of absorption from the liver 
surface.   Therefore, we compared the absorbability of several model compounds 
having different molecular weights. 
The following equation has been proposed with respect to the drug absorption 
from the stomach and small intestine via passive diffusion (Koizumi et al., 1964a,b), on 
the basis of the principle that the diffusibility of a substance in uniform solutions is 
approximately inversely proportional to the square root of the molecular weight of drug 







= +  (3) 
Where Pa represents the partition coefficient, and constants A and B are correction 
factor to Pa and constant for diffusion, respectively. 
Because each model compound has high hydrophilicity, the Pa is supposed to be 
identical approximately and the right side of Eq. (3) can be transformed as the fixed 
14 
number.   We examined the relationship between the Ka and the reciprocal value with 
square root of molecular weight (1/ Mw ) of the model compounds with different 
molecular weights, as illustrated in Figure 5.   The values for phenol red (PR, Mw: 
354), bromphenol blue (BPB, Mw: 670) and bromosulphonphthalein (BSP, Mw: 838) 
were reported previously (Nishida et al., 1994).   As shown in Figure 5, the increase 
in the molecular weight (i.e., the decrease in the 1/ Mw ) of the model compounds 
resulted in the decrease of the Ka.   A linear relationship was observed between the Ka 
and 1/ Mw  of the model compounds (correlation coefficient: 0.96), suggesting that 
the model compounds are absorbed from the rat liver surface membrane via simple 
passive diffusion. 
The liver is covered by serous membrane containing monolayer squamous 
epithelial cells.   And a space between the serous membrane and hepatic parenchymal 
cell is supported by connective tissue, in which the capillary of portal vein and hepatic 
artery circulates.   Therefore, the drug penetrated across the capillary wall in the 
connective tissue is flowed into the sinusoid.   Also, the possibility of direct diffusion 
of drug into the parenchymal cell must be taken into consideration.   The absorption 
of the model compounds from the liver surface might occur through the intercellular 
gap and pore in the serous membrane and connective tissue rather than the transcellular 
lipid route, since the hydrophilicity of the model compounds is high.   However, the 
rate-limiting step in the absorption from the liver surface was unknown from our present 
investigation. 
The molecular weight when the Ka value is 0 (x-intercept) was extrapolated to be 
71,195 from the plot in Figure 5.   We consider that the limit (so-called threshold 
value) of the molecular weight of the drug absorbed from the rat liver surface is 
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approximately 70,000, which is larger than that restricting the movement of 
macromolecules from the peritoneum (Mw: 50,000) reported by Flessner et al. (1985b) 
and Hirszel et al. (1984). 
FDs applied to the rat liver surface were accumulated in the liver to some extent 
(Table 2).   For the mechanism of accumulation of drug in the liver, the following 
route is considered, judging from the anatomical feature of the liver surface membrane.   
The drug flowed into the blood (sinusoid) circulation was taken up by the liver, and/or 
the drug diffused directly into the parenchymal cell.   The percent of dose recovered 
from the liver decreased gradually from 5.4 % for FD-4 to 2.0 % for FD-70 (Table 2).   
The recoveries of FD-4 and FD-10 in the liver were small, despite their good 
absorbability from the rat liver surface.   The reason for this phenomenon was 
considered as follows, absorbed FD-4 and FD-10 were rapidly cleared by urinary 
excretion, and/or FD-4 and FD-10 taken up by the liver flowed out into the systemic 
circulation. 
The amount of FD absorbed into the systemic circulation for 6 h was calculated 
by dividing AUCp for 6 h after application to the rat liver surface by AUCp of i.v. 
administration (Table 1), as 44.9 % for FD-4, 29.9 % for FD-10, 2.7 % for FD-40 and 
0.5 % for FD-70.   Therefore, the ratio of amount remaining in the liver to the amount 
absorbed into the systemic circulation at 6 h was calculated to be 0.12 for FD-4, 0.16 
for FD-10, 1.03 for FD-40 and 4.06 for FD-70.   This indicates that targeting efficacy 
was enhanced with an increase in the molecular weight and was marked for FD-40 and 
FD-70. 
Moreover, the liver / plasma concentration ratio of FDs after application to the rat 
liver surface was high ranging from 3.0 to 11.5, as compared with that of i.v. 
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administration.   The specific moieties for the liver need to be introduced to 
macromolecules, for enhancement of hepatic uptake and reduction of toxicity in the 
normal organ outside the liver.   The specific bioactive recognition system in the liver 
was appropriately added to macromolecules for more effective targeting, such as a 
receptor for terminal galactose (Ashwell and Harford, 1982) and/or non-specific 
association by electric cationic charge (Nishida et al., 1991; Takakura et al., 1990; 
Yamaoka et al., 1995a). 
Consequently, we clarified the absorption characteristics of FDs as model 
macromolecules from the liver surface in rats, and implied the possibility of this new 
administration route to improve the strategy for specific delivery of therapeutic agents 
to the diseased region in the liver.   According to the change in hepatic function, 
sinusoidal blood flow and nature of liver surface membrane and so on, the absorbability 
from the liver surface appears to be altered in the diseased liver.   Thus, a further 
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Pharmacokinetic parameters for FDs with different molecular weights after i.v. 
administration in rats at a dose of 5 mg 
 
 
 Compound K12 K21 Kel Vc CLtotal AUCp 
  (min-1) (min-1) (min-1) (ml) (ml/min) (µg/ml·min) 
 
 
 FD-4 0.292 0.108 0.137 13.7 1.875 2664 
  ±0.045 ±0.025 ±0.038 ±0.7 ±0.488 ±693 
 
 FD-10 0.167 0.131 0.158 13.2 2.078 2397 
  ±0.053 ±0.031 ±0.018 ±0.9 ±0.231 ±267 
 
 FD-40 0.020 0.016 0.011 11.4 0.112 39872 
  ±0.002 ±0.004 ±0.002 ±0.5 ±0.032 ±11392 
 
 FD-70 0.011 0.017 0.003 9.5 0.025 175439 
  ±0.001 ±0.003 ±0.001 ±0.4 ±0.004 ±28070 
 
 





Recovery (%) of FDs with different molecular weights at 6 or 3 h after 
application to the liver surface (LS) or i.v. administration in rats, respectively, at 
a dose of 5 mg 
 
 
 Compound  Glass cell     Bile     Urine     Liver   
 LS i.v. LS i.v. LS i.v. LS 
 
 
 FD-4 55.5 0.4 0.4 66.6 24.5 3.3 5.4 
  ±2.5 ±0.1 ±0.1 ±10.8 ±5.1 ±0.2 ±0.1 
 
 FD-10 70.7 0.5 0.4 73.0 18.9 3.9 4.9 
  ±2.7 ±0.1 ±0.1 ±2.6 ±3.2 ±1.6 ±0.1 
 
 FD-40 94.9 2.0 0.9 32.4 2.3 2.2 2.8 
  ±1.8 ±0.5 ±0.2 ±1.4 ±0.8 ±0.3 ±0.2 
 
 FD-70 97.8 2.6 0.5 5.8 0.3 1.1 2.0 
  ±1.0 ±0.2 ±0.1 ±1.8 ±0.1 ±0.3 ±0.3 
 
 




First-order absorption rate constant Ka (min-1 x 10-5) for FDs with different 
molecular weights after application to the rat liver surface 
 
 
 Source FD-4 FD-10 FD-40 FD-70 
 
 
 Elimination profilea 157.2 92.4 14.6 6.1 
 
 Curve-fittingb 156.4 117.3 12.3 3.7 
 
 
a Ka was estimated from the elimination profile of FDs amount remaining in the 
glass cell after application to the rat liver surface at a dose of 5 mg. 
b Ka was obtained from the curve-fitting of the plasma concentration profile of 




FIGURE 1.   Plasma concentration profiles of FD-4 (□), FD-10 (○), FD-40 (△) 
and FD-70 (▽) after i.v. administration in rats at a dose of 5 mg.   Curves show 
simulated functions based on the parameters shown in Table 1.   Each point represents 
the mean ± S.E. of at least four experiments. 
FIGURE 2.   Plasma concentration profiles of FD-4 (A), FD-10 (B), FD-40 (C) and 
FD-70 (D) after application to the rat liver surface at a dose of 5 mg.   Each point 
represents the mean ± S.E. of at least four experiments.   Solid and broken curves 
show simulated functions based on the pharmacokinetic parameters of FDs (Tables 1 
and 3) calculated by elimination profile from the glass cell or by curve-fitting of the 
plasma concentration profile, respectively. 
FIGURE 3.   Time courses of amount of FD-4 (A) and FD-10 (B) in the glass cell 
(○) and plasma (●), and their cumulative amount excreted into the bile (□) and 
urine (△) after application to the rat liver surface at a dose of 5 mg.   Each point 
represents the mean ± S.E. of at least four experiments. 
FIGURE 4.   Semi-log plots of time courses of the amount of FD-4 (□) and FD-10 
(○) remaining in the glass cell after application to the rat liver surface at a dose of 5 
mg.   Each point represents the mean ± S.E. of at least four experiments. 
FIGURE 5.   Relationship between the molecular weight (Mw) and first-order 
absorption rate constant (Ka) of the FDs (○) and the other model compounds (●) 
with different molecular weights.   The Ka value was calculated from the amount 
remaining in the glass cell at 6 h after application to the rat liver surface.   The values 
for phenol red (PR), bromphenol blue (BPB) and bromosulphonphthalein (BSP) were 
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